Tech Company Financing Transactions
Synthorx Funding Round
OrbiMed, Avalon Ventures and Correlation Ventures participated in a $63 million Series C capital raise for Synthorx. The round was announced by the company on 5/1/2018.
Transaction Overview
Company Name
Announced On
5/1/2018
Transaction Type
Venture Equity
Venture Equity
Venture Equity
Amount
$63,000,000
Round
Series C
Investors
OrbiMed (Lead Investor) (Peter Thompson)
Proceeds Purpose
The proceeds of the financing will be used to advance the company's pipeline of Synthorin cytokines, including an IL-2 tuned specifically for activity on certain immune cells.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11099 North Torrey Pines Rd. 290
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Synthorx is a biotechnology company using synthetic biology to discover and develop novel therapeutics, diagnostics and vaccines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laura Shawver
Chief Scientific Officer
Marcos Milla
Chief Scientific Officer
Floyd Romesberg
Browse more venture capital transactions:
Prev: 5/1/2018: LeaseLock venture capital transaction
Next: 5/1/2018: ClicData venture capital transaction
Share this article
News on VC Transactions
We document every notable VC transaction. VC transactions on this site come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs